TRTH is a rigorous year-long training and mentoring experience that helps junior scientists build successful careers in translational hematologic research. Under the guidance of international leaders, participants learn the fundamental principles related to translational research, including developing a hypothesis and testing that hypothesis in the laboratory by applying the scientific method.
TRTH participants include medical, biomedical, and pharmaceutical trainees who are actively employed in a hematology-related research environment as fellows or junior faculty who have completed their fellowship training within the past three years.
This year’s TRTH program will begin with a week-long course March 11-17 in Italy. It is designed to give participants a more profound understanding of translational research methodology and career development. The course includes didactic and interactive sessions and one-on-one faculty mentoring that focuses on refining participants’ research proposals. TRTH participants will convene again at the 2017 EHA Annual Congress, June 22-25 in Madrid, where they will attend small group mentoring sessions. Finally, participants will present the status of their projects at the conclusion of the program at the 2017 ASH Annual Meeting, December 9-12 in Atlanta.
The TRTH program is made possible by generous support from Celgene, Takeda Oncology, Janssen Pharmaceutica NV, AMGEN (EUROPE) GmbH, Bristol-Myers Squibb, Incyte Corporation, Gilead Sciences, Inc., Astellas Pharma, AstraZeneca, F. Hoffmann-La Roche Ltd.
“I’m pleased that ASH and EHA continue to offer this unique opportunity for junior scientists to learn the principles of translational research. This experience will give them the knowledge and support to turn their talents into discoveries that will count for patients,” said ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. “As a mentor myself, I am proud that ASH supports programs that train and support the next generation of scientists.”
The American Society of Hematology (ASH) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood.